CYLD mutations differentially affect splicing and mRNA decay in Brooke-Spiegler syndrome


Published in:
Journal of the European Academy of Dermatology and Venereology

DOI:
10.1111/jdv.14889

Publication date:
2018

Document Version
Peer reviewed version

Link to publication in Discovery Research Portal

Citation for published version (APA):
Article type: Letter to Editor

CYLD mutations differentially affect splicing and mRNA decay in Brooke-Spiegler syndrome

Lizelotte J.M.T. Parren1,2,3, Jens M. Baron4, Sylvia Joussen5, Yvonne Marquardt4, Sandra Hanneken6, Maurice A.M. van Steensel7,8, Peter M. Steijlen2,3, Michel van Geel2,3,9, and Jorge Frank10

1Department of Dermatology, Jeroen Bosch Hospital, 's-Hertogenbosch, The Netherlands;
2Department of Dermatology and 3GROW - School for Oncology and Developmental Biology, Maastricht University Medical Center (MUMC), The Netherlands;
4Department of Dermatology and Allergology, RWTH Aachen University, Aachen, Germany;
5Institute of Physiology, RWTH Aachen University, Aachen, Germany
6Private Practice Empoderm, Graf-Adolf-Strasse 88; 40210 Düsseldorf, Germany;
7Institute of Medical Biology, Immunos, Singapore
8Division of Cancer Science, College of Medicine, Dentistry and Nursing; Department of Biological Chemistry and Drug Discover, College of Life Sciences, University of Dundee, Dundee, UK
9Department of Clinical Genetics, Maastricht University Medical Center, Maastricht, The Netherlands
10Department of Dermatology, Venereology and Allergology, University Medical Center Göttingen, Göttingen, Germany

Subject category: Letter to the editor
Running title: CYLD splice site mutations
Address for correspondence:

Univ.-Prof. Dr. med. Jorge Frank, M.D.

Department of Dermatology, Venereology and Allergology

University Medical Center Göttingen

Robert-Koch-Str. 40

37075 Göttingen; Germany
Phone +49-551-3966402
Fax +49-551-3966841
e-mail jorge.frank@med.uni-goettingen.de

Statement of funding sources: None

Conflict of interest: None

ABBREVIATIONS

BSS Brooke-Spiegler syndrome
NHEK Normal human epidermal keratinocytes
PBMC Peripheral blood mononuclear cells
PTC Premature termination codon
qRT-PCR Quantitative reverse transcriptase polymerase chain reaction
RT-PCR Reverse transcriptase polymerase chain reaction

This article is protected by copyright. All rights reserved.
KEY WORDS
Brooke-Spiegler syndrome; CYLD; familial cylindromatosis; mRNA decay; splice site mutation

EDITOR,

Brooke-Spiegler syndrome (BSS; OMIM 605041), also known as familial cylindromatosis (OMIM 132700), is an autosomal dominant tumour predisposition disorder characterised by the occurrence of cylindromas, trichoepitheliomas, and spiradenomas. BSS is caused by heterogenous mutations in the CYLD gene. To date, different CYLD mutations have been reported, most of them resulting in a premature termination codon (PTC). Among these, thirteen splice site mutations have been described. However, it remains largely elusive how such mutations affect splicing.

Here, we studied three unrelated Caucasian patients with BSS who were initially diagnosed both clinically and histopathologically (Table 1). To unequivocally confirm the diagnosis, we performed mutation analysis of the CYLD gene which revealed three splice site mutations. In order to select appropriate tissues for RNA studies, we assessed the expression of CYLD in normal human epidermal keratinocytes (NHEK), leukocytes and peripheral blood mononuclear cells (PBMC) by quantitative reverse transcriptase (qRT)-PCR. In all patients, residual mRNA levels were measured in RNA specimens derived from whole blood.

We detected three CYLD splice site mutations, designated c.2108+1G>A (Fig. 1a), c.2242-2A>G (Fig. 1b), and c.2109-2A>C (Fig. 1c). These mutations were associated with distinct phenotypes, respectively (Table 1). Interestingly, the first patient carried a novel mutation
that was not detectable in either parent. Paternity was confirmed by haplotype analysis (data not shown). To the best of our knowledge, c.2108+1G>A represents the first de novo mutation reported in BSS. All mutations were shown by restriction enzyme digestion to be absent from 100 unrelated, unaffected Caucasian control individuals (data not shown).

Comparison of mRNA expression by RT-PCR revealed that CYLD is expressed at almost equal levels in NHEK, leukocytes and PBMC (data not shown). In the patients carrying mutations c.2108+1G>A and c.2242-2A>G, RT-PCR on RNA derived from PBMCs revealed the wild-type product containing 430 base pairs (bp) and a smaller additional band of 363 and 321 bp, respectively. Automated DNA sequencing showed that the smaller bands represented fragments excluding exons 15 and 17, respectively (data not shown). Both exon skipping events lead to putative out-of-frame translation and generation of a PTC. For mutation c.2108+1G>A the PTC is located 30 codons downstream of the mutation site (p.Pro682Gln31fs*) and for c.2242-2A>G, 47 codons downstream of the mutation (p.Ala748Leufs48*). Of note, we did not detect an aberrant splicing pattern for c.2109-2A>C. This finding suggested that the transcript of the mutated allele is subject to nonsense-mediated mRNA decay.

To study the role of nonsense-mediated mRNA decay in the three splice site mutations detected here, we measured CYLD mRNA expression in peripheral blood leukocytes by qRT-PCR. Whereas mutations c.2108+1G>A and c.2242-2A>G do not result in a significant decrease of mRNA levels, mutation c.2109-2A>C is associated with approximately 60% mRNA decay when compared to a control (Fig. 1d).

The patient harbouring mutation c.2109-2A>C presented with cylindromas exclusively. This mutation has been previously reported in a family with trichoepitheliomas only, which suggests that the residual amounts of CYLD mRNA seem to be unrelated to the distinct phenotypes of individuals with this CYLD splice site defect.4 To date, fifteen splice site

This article is protected by copyright. All rights reserved.
mutations have been reported to underlie different phenotypes, comprising Brooke-Spiegler syndrome (30%), familial cylindromatosis (35%), and multiple familial trichoepithelioma (35%). These previous reports and our own data confirm the previous notion that there is no apparent genotype-phenotype correlation in diseases caused by CYLD mutations. Possibly, as of yet unknown environmental factors, modifier genes or epigenetic events could contribute to the different phenotypes observed.

REFERENCES


**LEGENDS TO TABLE AND FIGURES**

**Table 1**  
*CYLD* splice site mutations in this study, associated phenotypes, and the structural and functional consequences of these mutations.

**Figure 1**  
a-c) Splice site mutations detected in this study, designated c.2108+1G>A; c.2242-2A>G; and c.2109-2A>C. d) Quantitative real-time PCR indicates that mutations C.2108+1G>A and C.2242-2A>G are not associated with relevant mRNA decay. By contrast, mutation C.2109-2A>C leads to substantial mRNA decay.

<table>
<thead>
<tr>
<th>Mutation</th>
<th>c.2108+1G&gt;A</th>
<th>c.2242-2A&gt;G</th>
<th>c.2109-2A&gt;C</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phenotype</td>
<td>Cylindromas and trichoepitheliomas</td>
<td>Cylindromas and trichoepitheliomas</td>
<td>Cylindromas</td>
</tr>
<tr>
<td>Novel or recurrent mutation</td>
<td>Novel</td>
<td>Novel</td>
<td>Recurrent</td>
</tr>
<tr>
<td>Consequence of splicing defect</td>
<td>Exon skipping</td>
<td>Exon skipping</td>
<td>Nonsense-mediated mRNA decay</td>
</tr>
<tr>
<td>Levels of mRNA</td>
<td>Normal</td>
<td>Normal</td>
<td>40% of normal</td>
</tr>
</tbody>
</table>

Table 1  
*CYLD* splice site mutations in this study, associated phenotypes as well as the structural and functional consequences of these mutations.